Edwards Lifesciences (EW) Misses Q2 EPS by 1c, Q3 Revenue Guidance Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Edwards Lifesciences (EW) Down on Earnings Miss as Hospital Staffing 'Remains Uncertain'
July 29, 2022 1:32 PM EDTEdwards Lifesciences (NYSE: EW) shares have fallen over 6% Friday on the back of its earnings release.
The company reported after the close Thursday, missing earnings and revenue expectations.
Edwards Lifesciences reported earnings of $0.63, $0.01 worse than the analyst estimate of $0.64 on revenue of $1.37 billion, missing the consensus estimate of $1.4 billion.
The company said it experienced persistent disruption within the healthcare... More
